Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Compare the Immunogenicity, Reactogenicity & Safety of 2 Different Formulations of GSK Biologicals' Live Attenuated Human Rotavirus (HRV) Vaccine Given as a Two-dose Primary Vaccination in Healthy Infants Previously Uninfected With HRV
Brief Summary: Rotavirus (RV) is the most important cause of acute gastroenteritis (GE) requiring the hospitalization of infants and young children in developed and developing countries and can be a frequent cause of death in children less than 5 years of age (estimated nearly 500,000 annual deaths worldwide). GlaxoSmithKline (GSK) Biologicals has developed a vaccine against human rotavirus gastroenteritis. A new formulation of the vaccine, with an alternative buffer, was developed. This study will be conducted to evaluate the new formulation compared to the existing formulation of the HRV vaccine.


Options:
A: Intervention Type: BIOLOGICAL; Name: Live attenuated rotavirus vaccine; Assigned to Arm(s): N/A
B: Arm Label: Group 1: Concomitant Administration; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq®, Biological: NeisVac-C® | Arm Label: Group 2: Sequential Administration; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq®, Biological: NeisVac-C® | Intervention Type: BIOLOGICAL; Name: RotaTeq®; Assigned to Arm(s): Group 1: Concomitant Administration, Group 2: Sequential Administration | Intervention Type: BIOLOGICAL; Name: NeisVac-C®; Assigned to Arm(s): Group 1: Concomitant Administration, Group 2: Sequential Administration
C: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals' liquid human rotavirus vaccine 444563, Biological: Infanrix™, Biological: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV) | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Infanrix™, Biological: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV) | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' liquid human rotavirus vaccine 444563; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group | Intervention Type: BIOLOGICAL; Name: Infanrix™; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV); Assigned to Arm(s): Placebo Group, Rotarix Group
D: Arm Label: Cohort A P2-VP8 30 mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 30 mcg | Arm Label: Cohort A Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Cohort A P2-VP8 60 mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 60mcg | Arm Label: Cohort B P2-VP8 10mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 10mcg | Arm Label: Cohort B placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Cohort B P2-VP8 30mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 30 mcg | Arm Label: Cohort B1 P2-VP8 60mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 60mcg | Arm Label: Cohort A P2-VP8 10mcg; Type: EXPERIMENTAL; Interventions: Biological: P2-VP8 Subunit Vaccine 10mcg | Intervention Type: BIOLOGICAL; Name: P2-VP8 Subunit Vaccine 10mcg; Assigned to Arm(s): Cohort A P2-VP8 10mcg, Cohort B P2-VP8 10mcg | Intervention Type: BIOLOGICAL; Name: P2-VP8 Subunit Vaccine 30 mcg; Assigned to Arm(s): Cohort A P2-VP8 30 mcg, Cohort B P2-VP8 30mcg | Intervention Type: BIOLOGICAL; Name: P2-VP8 Subunit Vaccine 60mcg; Assigned to Arm(s): Cohort A P2-VP8 60 mcg, Cohort B1 P2-VP8 60mcg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Cohort A Placebo, Cohort B placebo

Answer: A